Publication Information

{'id': 'https://openalex.org/W2952329847', 'doi': None, 'title': 'Dr. Hussein Abdul-Hassan Tawbi on Oral Azacitidine Plus Pembrolizumab in Metastatic Melanoma', 'display_name': 'Dr. Hussein Abdul-Hassan Tawbi on Oral Azacitidine Plus Pembrolizumab in Metastatic Melanoma', 'publication_year': 2019, 'publication_date': '2019-06-13', 'ids': {'openalex': 'https://openalex.org/W2952329847', 'mag': '2952329847'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://www.cancernetwork.com/asco-melanoma/dr-hussein-abdul-hassan-tawbi-oral-azacitidine-plus-pembrolizumab-metastatic-melanoma', 'pdf_url': None, 'source': None, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5056045921', 'display_name': 'Hussein Tawbi', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': True, 'raw_author_name': 'Hussein Abdul-Hassan Tawbi', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': ['https://openalex.org/A5056045921'], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 61}, 'biblio': {'volume': None, 'issue': None, 'first_page': None, 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9978, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9978, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10580', 'display_name': 'Immunotherapy and Immune Responses', 'score': 0.9799, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T11736', 'display_name': 'Histone Deacetylase Inhibitors Research', 'score': 0.9785, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [], 'concepts': [{'id': 'https://openalex.org/C2780057760', 'wikidata': 'https://www.wikidata.org/wiki/Q13896859', 'display_name': 'Pembrolizumab', 'level': 4, 'score': 0.844777}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.6319768}, {'id': 'https://openalex.org/C2777658100', 'wikidata': 'https://www.wikidata.org/wiki/Q180614', 'display_name': 'Melanoma', 'level': 2, 'score': 0.41637135}, {'id': 'https://openalex.org/C2994587330', 'wikidata': 'https://www.wikidata.org/wiki/Q180614', 'display_name': 'Metastatic melanoma', 'level': 3, 'score': 0.41153556}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.34002686}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.3327242}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.23681721}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.19636288}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.18795559}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://www.cancernetwork.com/asco-melanoma/dr-hussein-abdul-hassan-tawbi-oral-azacitidine-plus-pembrolizumab-metastatic-melanoma', 'pdf_url': None, 'source': None, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.81}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': [], 'abstract_inverted_index': {'Cancer': [0], 'Network': [1], 'spoke': [2], 'with': [3, 22], 'Hussein': [4], 'Abdul-Hassan': [5], 'Tawbi,': [6], 'MD,': [7], 'PhD,': [8], 'on': [9], 'the': [10], 'results': [11], 'of': [12, 17], 'a': [13], 'phase': [14], 'II': [15], 'study': [16], 'oral': [18], 'azacitidine': [19], 'in': [20, 24], 'combination': [21], 'pembrolizumab': [23], 'metastatic': [25], 'melanoma.': [26]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2952329847', 'counts_by_year': [], 'updated_date': '2024-12-07T06:04:55.244616', 'created_date': '2019-06-27'}